ScripJazz and Roche can both expect a sales boost after a combination of their drugs has improved overall survival in extensive-stage small-cell lung cancer (SCLC). Full data from the Phase III IMforte tri
ScripBristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech
ScripAstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu (trastuzumab deruxtecan), used in combination with Roche’s HER2-targeting Perjeta (pertuzumab), has potential to change
ScripAstraZeneca’s Phase III SERENA-6 study of camizestrant could usher in a new treatment paradigm by using biomarker testing to detect emerging resistance in breast cancer and change therapy without wait